Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | PHASE3 | RECRUITING | 10 | — | — | Mar 31, 2025 | Sep 17, 2027 | Mar 23, 2026 | 7 | United States, Canada +1 |
| Arm | Type | Description |
|---|---|---|
| VX-880 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Biological/Vaccine | BIOLOGICAL | Infused into the hepatic portal vein. |
Key Inclusion Criteria: * Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence * Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks * Consistent use of continuous glucose monito...